Friday, January 30, 2015
YOLO COUNTY NEWS
99 CENTS

Sickle cell drug shows promise in UCD trial

By
From page A8 | July 06, 2014 |

A UC Davis clinical trial has found safe a drug designed to treat a common, painful complication of sickle cell disease.

There are currently no specific treatments for vaso-occlusive crises, during which clumped-together blood cells hinder blood flow. It is responsible for more than 70,000 hospitalizations annually, according to Ted Wun, associate dean for research at the UCD School of Medicine.

The 15-patient trial found no severe side-effects from the drug, dubbed GMI 1070, and that it was maintaining adequate concentrations in the blood.

Published online in the journal Public Library of Science ONE, the study was not aimed at determining the drug’s effectiveness, but Wun said it did show small improvements in blood flow and reduced the markers of cell activation.

Sickle cell disease, which lowers life expectancy by 20 to 30 years, affects an estimated 90,000 to 100,000 Americans, mostly blacks, according to the U.S. Centers for Disease Control and Prevention.

It is caused by abnormal hemoglobin that contorts red blood cells into a sickle shape, making them stiff and sticky. These clumped cells reduce blood flow, leading to severe hip, back and long-bone pain, and, often, chest and abdominal pain.

“White blood cells bind to inflamed blood vessel walls and sickle red cells stick to white cells, but interestingly the initiating event is the white cells,” Wun said in a news release. “If we could interrupt that white cell interaction, we could stop the cycle that leads to vaso-occlusions.”

The new drug is designed to do that by mimicking sugars attached to cell-adhesion proteins, called selectins, reducing the stickiness and increasing blood flow.

Sickle cell most often strikes the kidneys, lungs and spleen, but it can affect any organ. Stroke, infections, hypertension and heart failure are among its severe complications.

Patients in the trial tolerated the drug well, with headaches the most common side-effect. Preliminary results of a second trial also have been positive, and have been submitted for publication, according to researchers. A third phase is planned.

“If the phase III study confirms that GMI 1070 is effective, it would be a huge advance for the sickle cell community,” Wun said.

GlycoMimetics Inc., a Maryland-based biotechnology company based in Gaithersburg, produces the new drug under the trade name Rivipansel. The company paid for the trial.

Also this week, National Institutes of Health scientists announced the results of a study that found bone marrow transplants can reverse sickle cell disease. The transplant worked in 26 of 30 adults, and 15 of them were even able to stop taking drugs that prevent rejection one year later.

The treatment is a modified version of bone marrow transplants that have worked in children. Donors are a brother or sister whose stem cell-rich bone marrow is a good match for the patient.

The treatment involves using chemotherapy and radiation to destroy bone marrow before replacing it with healthy donor marrow cells.

Results from the adult study, involving patients aged 29 on average, were published in the Journal of the American Medical Association.

—The Associated Press contributed to this report.

Comments

comments

Cory Golden

Cory Golden

The Enterprise's higher-education and congressional reporter. http://about.me/cory_golden
  • Recent Posts

  • Enter your email address to subscribe to this newspaper and receive notifications of new articles by email.

  • .

    News

    Suspected Ebola patient being treated at UCD Med Center

    By San Francisco Chronicle | From Page: A1

     
    Town hall focuses on Coordinated Care Initiative

    By Anne Ternus-Bellamy | From Page: A1

    Schools give parents tools to help kids thrive

    By Enterprise staff | From Page: A1 | Gallery

     
    Need a new best friend?

    By Enterprise staff | From Page: A2 | Gallery

     
    Stanford University to get $50 million to produce vaccines

    By The Associated Press | From Page: A2

    Two more cases of measles in Northern California in children

    By The Associated Press | From Page: A2

     
    Dartmouth bans hard liquor

    By New York Times News Service | From Page: A2

     
    Walkers head out three times weekly

    By Enterprise staff | From Page: A3Comments are off for this post

    Free tax preparation service begins Monday

    By Special to The Enterprise | From Page: A3

     
    Vote for your favorites in Readers’ Choice poll

    By Enterprise staff | From Page: A3

    No bare bottoms, thanks to CommuniCare’s Diaper Drive

    By Special to The Enterprise | From Page: A3 | Gallery

     
    Storyteller relies on nature as his subject on Saturday

    By Enterprise staff | From Page: A3

    Still time to purchase tickets for DHS Cabaret

    By Enterprise staff | From Page: A3

     
    All voices welcome at sing-along Wednesday

    By Enterprise staff | From Page: A3

    Great Chefs Program will feature Mulvaney

    By Special to The Enterprise | From Page: A3

     
    Take a photo tour of Cuba at Flyway Nights talk

    By Enterprise staff | From Page: A6 | Gallery

     
    February science fun set at Explorit

    By Lisa Justice | From Page: A6 | Gallery

    See wigeons, curlews and meadowlarks at city wetlands

    By Special to The Enterprise | From Page: A8 | Gallery

     
    .

    Forum

    Time for bed … with Grandma

    By Creators Syndicate | From Page: B5

     
    Protect root zone to save trees

    By Letters to the Editor | From Page: A10

    Weigh quality of life, density

    By Letters to the Editor | From Page: A10

     
    Olive expert joins St. James event

    By Letters to the Editor | From Page: A10

    We’re grateful for bingo proceeds

    By Letters to the Editor | From Page: A10

     
    Tom Meyer cartoon

    By Debbie Davis | From Page: A10

     
    A ‘new deal’ for the WPA building

    By Special to The Enterprise | From Page: A10

    .

    Sports

    Mustangs hold off UCD women

    By Enterprise staff | From Page: B1 | Gallery

     
    UCD men set new school D-I era win record

    By Bruce Gallaudet | From Page: B1 | Gallery

    UCD has another tough football schedule in 2015

    By Enterprise staff | From Page: B1

     
    Gould’s influence felt mightily in recent Super Bowls

    By Bruce Gallaudet | From Page: B1

    Sharks double up Ducks

    By The Associated Press | From Page: B2 | Gallery

     
    Sports briefs: Watney, Woods start slow at TPC Scottsdale

    By Enterprise staff | From Page: B2

    Recall that first Aggie TV game, national title?

    By Bruce Gallaudet | From Page: B8 | Gallery

     
    .

    Features

    .

    Arts

    ‘Song of the Sea’ is an enchanting fable

    By Derrick Bang | From Page: A11 | Gallery

     
    ‘Artist’s Connection’ launches on DCTV

    By Special to The Enterprise | From Page: A11

     
    Gross’ paintings highlight a slice of Northern California

    By Enterprise staff | From Page: A12 | Gallery

    February show at YoloArts’ Gallery 625 is ‘Food for Thought’

    By Special to The Enterprise | From Page: A12 | Gallery

     
    .

    Business

    .

    Obituaries

    .

    Comics

    Comics: Friday, January 30, 2015

    By Creator | From Page: A9